Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 12/20 | 0.73 |
| ▸ | MAPT | P10636 | 11/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | VDR | P11473 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25010118 | 0.94 | TP53 (0.79) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25010473 | 0.94 | TP53 (0.63) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25011030 | 0.94 | TP53 (0.82) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25011049 | 0.89 | TP53 (0.85) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25009593 | 0.89 | TP53 (0.87) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25009659 | 0.89 | TP53 (0.63) | TP53MAPTSMN1; SMN2VDRTHRB | |
| SCHEMBL25010462 | 0.88 | TP53 (0.69) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25009182 | 0.87 | TP53 (0.91) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL23416180 | 0.87 | VDR (0.57) | TP53MAPTSMN1; SMN2VDRPOLB | |
| SCHEMBL25010122 | 0.86 | TP53 (0.85) | TP53MAPTSMN1; SMN2VDRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | TP53 376/4885MAPT 2111/4885SMN1; SMN2 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.